Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia

Experimental Hematology and Oncology

Volumn 2, Issue 1, 2013, Pages

  Gimenes Teixeira, Hamilton L ^a   Lucena Araujo, Antonio R ^a   dos Santos, Guilherme A ^a   Zanette, Dalila L ^a   Scheucher, Priscila S ^a   Oliveira, Luciana C ^a   Dalmazzo, Leandro F ^a   Silva Júnior, Wilson A ^a   Falcão, Roberto P ^a   Rego, Eduardo M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CD56; miRNA; T cell acute lymphoid leukemia; Treatment outcome

Indexed keywords

CD56 ANTIGEN; MICRORNA; MICRORNA 221; MICRORNA 374; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; ONSET AGE; OVERALL SURVIVAL; PREDICTIVE VALUE; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA GENE; T CELL LEUKEMIA; T LYMPHOCYTE; T-CELL LEUKEMIA CELL LINE; THYMOCYTE;

EID: 84978023959     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-2-10     Document Type: Article

References (33)

1. Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. Int J Hematol 2003, 78:7-17. 10.1007/BF02983234, 12894845.
2. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1093-1101. 10.1016/S1470-2045(09)70265-7, 19880063.
3. Harabuchi Y, Takahara M, Kishibe K, Moriai S, Nagato T, Ishii H. Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol 2009, 14:181-190. 10.1007/s10147-009-0882-7, 19593607.
4. Dalmazzo LF, Jacomo RH, Marinato AF, Figueiredo-Pontes LL, Cunha RL, Garcia AB, et al. The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. Br J Haematol 2009, 144:223-229. 10.1111/j.1365-2141.2008.07457.x, 19016721.
5. Montero I, Rios E, Parody R, Perez-Hurtado JM, Martin-Noya A, Rodriguez JM. CD56 in T-cell acute lymphoblastic leukaemia: a malignant transformation of an early myeloid-lymphoid progenitor?. Haematologica 2003, 88:ELT26.
6. Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994, 180:569-576. 10.1084/jem.180.2.569, 2191594, 7519241.
7. Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1995, 85:3538-3546.
8. Kirigin FF, Lindstedt K, Sellars M, Ciofani M, Low SL, Jones L, et al. Dynamic microRNA gene transcription and processing during T cell development. J Immunol 2012, 188:3257-3267. 10.4049/jimmunol.1103175, 22379031.
9. Liu TY, Chen SU, Kuo SH, Cheng AL, Lin CW. E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol 2010, 23:1507-1517. 10.1038/modpathol.2010.139, 20802470.
10. Gantier MP. New perspectives in MicroRNA regulation of innate immunity. J Interferon Cytokine Res 2010, 30:283-289. 10.1089/jir.2010.0037, 20477549.
11. Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, De Haas V, Trka J, et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer 2012, 58:715-721. 10.1002/pbc.23279, 21818844.
12. Han BW, Feng DD, Li ZG, Luo XQ, Zhang H, Li XJ, et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011, 20:4903-4915. 10.1093/hmg/ddr428, 3221537, 21926415.
13. Schotte D, De Menezes RX, Akbari MF, Khankahdani LM, Lange-Turenhout E, Chen C, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011, 96:703-711. 10.3324/haematol.2010.026138, 3084917, 21242186.
14. Wang P, Gu Y, Zhang Q, Han Y, Hou J, Lin L, et al. Identification of resting and type I IFN-activated human NK cell miRNomes reveals microRNA-378 and microRNA-30e as negative regulators of NK cell cytotoxicity. J Immunol 2012, 189:211-221. 10.4049/jimmunol.1200609, 22649192.
15. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, et al. Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica 2010, 95:1114-1121. 10.3324/haematol.2009.015099, 2895035, 20418243.
16. Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011, 43:673-678. 10.1038/ng.858, 21642990.
17. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem 2012, 287:13952-13958. 10.1074/jbc.M111.321646, 3340184, 22396537.
18. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 2009, 284:3728-3738. 2635044, 19088079.
19. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010, 115:51-60. 10.1182/blood-2009-06-223719, 2803691, 19880494.
20. Huang X, Shen Q, Chen S, Chen S, Yang L, Weng J, et al. Gene expression profiles in BCL11B-siRNA treated malignant T cells. J Hematol Oncol 2011, 4:23. 10.1186/1756-8722-4-23, 3113752, 21575156.
21. Li L, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science 2010, 329:89-93. 10.1126/science.1188989, 2935300, 20595614.
22. Li P, Burke S, Wang J, Chen X, Ortiz M, Lee SC, et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science 2010, 329:85-89. 10.1126/science.1188063, 3628452, 20538915.
23. Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, et al. Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2010, 3:44. 10.1186/1756-8722-3-44, 2992472, 21080944.
24. Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006, 107:4500-4507. 10.1182/blood-2005-09-3801, 16484591.
25. Le Sage C, Nagel R, Agami R. Diverse ways to control p27Kip1 function: miRNAs come into play. Cell Cycle 2007, 6:2742-2749. 10.4161/cc.6.22.4900, 17986865.
26. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010, 107:264-269. 10.1073/pnas.0907904107, 2806773, 20018759.
27. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007, 14:791-798. 10.1677/ERC-07-0129, 17914108.
28. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008, 68:2745-2754. 10.1158/0008-5472.CAN-07-2538, 18417445.
29. Fischer L, Gokbuget N, Schwartz S, Burmeister T, Rieder H, Bruggemann M, et al. CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica 2009, 94:224-229. 10.3324/haematol.13543, 2635409, 19109214.
30. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SW, et al. Introduction and overview of the classification of the lymphoid neoplasms. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 2008, 157-267. International Agency for Reasearch on Cancer (IARC), Lyon, Swerdlow SH, Elias C, Nancy Lee H, Jaffe ES, Pileri SA, Harald S, 4.
31. Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000, 14:1381-13xi.
32. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000, 95:3310-3322.
33. Scrideli CA, Assumpcao JG, Ganazza MA, Araujo M, Toledo SR, Lee ML, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009, 94:781-789. 10.3324/haematol.2008.003137, 2688569, 19483156.